← Back to Search

Acidosis avoidance for Kidney Failure (RADAR-A Trial)

N/A
Waitlist Available
Led By David Charytan, MD, MSc
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Maintenance hemodialysis therapy for end-stage renal disease
Age 18-85 years (subjects between 18-40 years old will be required to have at least one of the following: history of congestive failure, diabetes, coronary or peripheral vascular disease, or arrhythmia)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

RADAR-A Trial Summary

This trial will test how well a standardized algorithm for changing the dialysate can lower the risk of abnormal heart rhythms in people with kidney failure.

Eligible Conditions
  • Kidney Failure

RADAR-A Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

RADAR-A Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adherence With Proposed Interventions
Mean Monthly Duration of Clinically Significant Arrhythmia (CSA)
Number of Participants Enrolled Per Month
+2 more
Secondary outcome measures
All-Cause Mortality
Cardiovascular Mortality
Incidence of Hospitalization
+4 more
Other outcome measures
Association of demographic and pre-randomization factors with adverse events
Association of dialysis day, shift, and site with CSA
Association of dialysis day, shift, and site with adherence
+1 more

RADAR-A Trial Design

4Treatment groups
Experimental Treatment
Group I: Potassium Removal Maximization StrategyExperimental Treatment3 Interventions
Dialysate potassium will be adjusted according to the results of point of care testing in order to maximize potassium removal and avoid hyperkalemia.
Group II: Potassium Gradient Minimization StrategyExperimental Treatment3 Interventions
Dialysate potassium will be adjusted according to the results of point of care testing in order to minimize the flux of potassium.
Group III: Alkalosis Avoidance StrategyExperimental Treatment3 Interventions
Dialysate bicarbonate concentration will be adjusted according to the results of point of care testing in order to prioritize avoiding alkalosis.
Group IV: Acidosis Avoidance StrategyExperimental Treatment3 Interventions
Dialysate bicarbonate concentration will be adjusted according to the results of point of care testing in order to prioritize avoiding acidosis.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Point of Care Testing
2018
N/A
~20
Cardiac Monitor
2018
N/A
~20

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,358 Previous Clinical Trials
816,794 Total Patients Enrolled
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,814 Previous Clinical Trials
47,290,856 Total Patients Enrolled
1 Trials studying Kidney Failure
402 Patients Enrolled for Kidney Failure
Duke UniversityOTHER
2,351 Previous Clinical Trials
3,409,527 Total Patients Enrolled
4 Trials studying Kidney Failure
1,595 Patients Enrolled for Kidney Failure

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~3 spots leftby Mar 2025